Inovio Biomedical Corporation was founded in 1983 and is based in San Diego, California. Inovio Biomedical Corporation engages in the design, development, and delivery of a new generation of vaccines, called DNA vaccines, focused on cancers and infectious diseases. The company's SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. Inovio's proprietary electroporation DNA delivery technology uses brief, controlled electrical pulses to increase cellular DNA vaccine uptake. The company also has access to formulation and manufacturing expertise, and technology through its controlling ownership in VGX International. Inovio's clinical programs include trials for HPV/cervical cancer (therapeutic) and HIV vaccines; and an IND has been filed for an avian influenza vaccine. Its partners and collaborators include Merck, Tripep, University of Southampton, University of Pennsylvania, HIV Vaccines Trial Network, NIH Vaccine Research Center, and National Microbiology Laboratory of the Public Health Agency of Canada. The company was formerly known as Genetronics Biomedical Corp. and changed its name to Inovio Biomedical Corporation in March 2005.

New Brunswick Scientific Co. was founded in 1946 and is headquartered in Edison, New Jersey. As of September 24, 2007, New Brunswick Scientific Co. Inc. is a subsidiary of Eppendorf AG. New Brunswick Scientific Co., Inc. and its subsidiaries provide various research equipment and scientific instruments for the life sciences industry. It engages in the design, manufacture, and marketing of equipment that creates, maintains, measures, and controls the physical and biochemical conditions required for the growth, detection, and storage of biological cultures. The company’s products include fermentation equipment, bioreactors, biological shakers, ultra-low temperature freezers, CO2 incubators, nutrient sterilizing and dispensing equipment, tissue culture apparatus, and air samplers. Its products are used in medical, biological, chemical, and environmental research; and for the commercial development of antibiotics, proteins, hormones, enzymes, monoclonal antibodies, agricultural products, fuels, vitamins, vaccines, and other substances. The company sells its equipment to biotechnology and pharmaceutical companies; agricultural and chemical companies; other industrial customers engaged in biotechnology; and medical schools, universities, research institutes, hospitals, and private laboratories; and laboratories of federal, state, and municipal government departments and agencies. It also sells its equipment directly, as well as through scientific equipment dealers to foreign companies, institutions, and governments. The company primarily operates in the United States, Asia, and Europe.

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel small molecule drugs for the treatment of diseases with high unmet need, including cancer and HIV infection. Its pipeline includes clinical and pre-clinical product candidates with mechanisms of action and novel chemical structures. The company's product candidates in clinical development include Azixa (MPC-6827), which is under Phase II clinical trial for the treatment of glioblastoma multiforme and metastatic melanoma; MPC-4326 for HIV-1 infection under Phase IIb clinical trial; and MPC-3100, a Phase I clinical trial product candidate for cancer treatment. Its products in preclinical programs comprise MPI-443803, an orally available, brain penetrant, microtubule destabilizing agent for the treatment of cancer; and MPI-461359, an orally available maturation inhibitor for the treatment of HIV-1 infection, as well as MPI-479605 for the treatment of cancer. The company also offers ProNet, a proprietary database of protein-protein interactions, which encompasses interactions between approximately 10 million protein fragments constructed from various organ tissues, including heart, brain, kidney, liver, breast, and prostate. Myriad Pharmaceuticals, Inc. is based in Salt Lake City, Utah.

Volu-Sol Reagents Corp company manufactures diagnostic products for use by clinical laboratories; it also plans to provide personal emergency response products and services for consumers. The company's diagnostic business develops and manufactures chemical reagents, stains, and related equipment used by laboratories to detect certain properties in biological samples in fields such as hematology and microbiology. Volu-Sol's yet to be launched Insight Care services employ biosensors, cell phone, and GPS technology to remotely monitor a client's vital signs and provide assistance. Parent RemoteMDx is spinning off Volu-Sol to shareholders. Founded in 1991, ActiveCare (formerly Volu-Sol) has been aided by some of the world’s largest companies, including Matsushita Electric Works (Panasonic), which was not only an investor in the company, but has helped to shape its technologies.

Kendle International Inc. was founded in 1981 and is based in Cincinnati, Ohio. Kendle International Inc. is a global clinical research organization (CRO) that provides a range of Phase I-IV global clinical development services to the biopharmaceutical industry. The Company augments the research and development activities of biopharmaceutical companies by offering clinical research services and information technology designed to reduce drug development time and expense. Kendle International Inc. is managed in two reportable segments: Early Stage and Late Stage. The Early Stage business focuses on the Company’s Phase I operations while Late Stage is comprised of clinical development services related to Phase II through III clinical trials conducted worldwide, late phase clinical development services related to Phase IIIB and IV clinical trials conducted worldwide, regulatory affairs and biometrics offerings. In June 2008, the Company announced the acquisition of DecisionLine Clinical Research Corporation.

CEO Alexander Kozak founded D-Pharm Ltd. in 1993. D-Pharm de-velops and de-livers biopharmaceuticals to treat a variety of diseases. The company focuses on discovery and development of lipid-based compounds used primarily against central nervous system disorders. Drugs currently approaching the market include treatments for epilepsy, bipolar disorder, and stroke. The company's pipeline also includes drugs intended to fight Alzheimer's disease, Parkinson's disease, psoriasis, bowel disease, and cancer. D-Pharm partners with other drug companies to bring its treatments to market.

ConjuChem Biotechnologies Inc. (ConjuChem) is a Canadian biotechnology company dedicated to the discovery of therapeutics with an initial focus on diabetes. The Company is focused on discovering and developing new drugs based on its technology platforms called Drug Affinity Complex (DAC) and Preformed Conjugate-Drug Affinity Complex (PC-DAC). The Company has developed the DAC Technology, a platform that enables the rapid creation of improved, patentable drugs from existing small organic compounds or peptides. The Company also designs drugs to treat an array of pathologies, such as diabetes, cancer and human immunodeficiency virus (HIV). ConjuChem has multiple research programs in-house and has one product in clinical trials.

Cangene Corporation company makes plasma products known as hyperimmunes, which are antibody preparations and recombinant biopharmaceuticals made by introducing a gene in a host organism. Cangene's drugs are used to treat plasma-derived disorders, including the blood clotting disorder thrombocytopenic purpura and hemolytic disease of the newborn, which occurs when a fetus' blood type is incompatible with its mother's. Cangene has several approved products and is developing others, mainly in the areas of infectious disease and biodefense. Generic giant Apotex owns more than 80% of Cangene.

Abaxis was founded in 1989 and is headquartered in Union City, California. Abaxis, Inc. develops, manufactures, markets, and sells portable blood analysis systems for use in the human or veterinary patient-care setting to provide clinicians with rapid blood constituent measurements in the medical and veterinarian markets worldwide. Its products include Point-Of-Care Blood Chemistry Analyzer, which performs a panel of 14 tests on human patients and 13 tests on veterinary patients marketed under the Piccolo xpress and Piccolo Classic names in the human medical market and under the VetScan VS2 and VetScan Classic names in the veterinary market. The company's products also include Reagent Discs that handle various technical steps of blood chemistry testing automatically; and VetScan HM5, VetScan HM2, VetScan HMII, and VetScan HMT hematology instruments, which offer blood count analysis for veterinary applications. In addition, its products comprise VetScan VSpro that assists in the diagnosis and evaluation of suspected bleeding disorders, toxicity/poisoning, evaluation of disseminated intravascular disease, hepatic disease and monitoring therapy, and progression of disease states; and VetScan Canine Heartworm Rapid Test, a test for the detection of dirofilaria immitis in canine whole blood, serum, or plasma. Further, Abaxis's products consist of Orbos Discrete Lyophilization Process, which allows the production of active chemical ingredient in the form of a soluble bead, as well as involves in flash-freezing a drop of liquid reagent to form a solid bead and then freeze-drying the bead to remove water. The company markets and sells its products through a direct sales force in the United States and through independent distributors.

New Leaf Brands, Inc. engages in the development, marketing, and distribution of ready-to-drink (RTD) beverages. Products The company’s New Leaf brand is a natural tea sweetened with organic cane sugar and specifically formulated to address the market for a healthy but appealing beverage. New Leaf is available in 13 flavors, integrating blue teas, green teas, black teas, and white teas. New Leaf products consist of Blue Teas, such as Diet Blue Tea with Lemon, Diet Blue Tea with Peach, Blue Tea with Lemon, Blue Tea with Peach, and Blue Tea with Raspberry; Green Teas, such as Green Tea with Plum, Green Tea with Ginseng, and Green Tea with Mango; White Teas, such as White Tea with Ginseng & Honey, White Tea with Honey Dew Melon, White Tea with Strawberry, and White Tea with Tangerine; and Black Tea: Mint & Lime International Sales The company sells its New Leaf brands in Canada and the Carribean. Customers New Leaf Tea is marketed to distributors, such as natural food, gourmet food, and mainstream distributors. The company’s major distributor is Manhattan Beer. Competition The company competes with soft drink companies, such as Coca Cola, Pepsi, and Cadbury Schweppes. In addition, it competes with beverage companies, including Arizona, Snapple, Lipton Brisk, Sobe, Vitamin Water, Fuze, Nestea, Tazo, Honest Tea, and Sweet Leaf Tea. Dispositions On October 9, 2009, the company completed the sale of its nutraceutical business, Nutritional Specialties, Inc. History The company was incorporated in 1986. It was formerly known as Baywood International, Inc. and changed its name to New Leaf Brands, Inc. on October 19, 2009.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.